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article under the CC BY-NC-ND licenseAbstract Objective: To assess the clinicopathological features and overall survival between
two groups of Chinese patients older or younger than 70 years after retropubic radical prosta-
tectomy.
Methods: From January 2001 to February 2010, 390 patients receive dretropubic radical pros-
tatectomy. After excluding 89 patients with adjuvant or neoadjuvant hormonal therapy or
radiotherapy, a total of 301 patients were included in this study. We arbitrarily divided these
patients into younger age group (<70 years, 140 cases, 46.5%) and older age group (70 years,
161 cases, 53.5%). The differences in serum prostate specific antigen (PSA), Gleason score,
clinical tumor stage, and biochemical-free survival were analyzed between the two groups.
Results: There were not significant differences between the two groups in high Gleason score
rate and clinical tumor stage. However, older patients had significantly lower biochemical
recurrence rate than those of younger patients, and had significantly higher PSA levels. Multi-
variate analysis showed that older age, PSA level and clinical tumor stage were significantly
associated with biochemical recurrence free survival.
Conclusion: In Chinese men, older age (70 years) is associated with better outcome. If the
physical condition permits, older age alone should not exclude patients from radical prostatec-
tomy.
ª 2015 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier
(Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).m.cn (Y. Sun).
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In 2013, prostate cancer was the most commonly diag-
nosed malignancy and the second leading cause of cancer-
related death in men in America [1]. However, the inci-
dence rate of prostate cancer in China is significantly
lower. A study had reported a 26-fold higher incidence
rate of prostate cancer in American than in Chinese men
with an intermediate rate in Chinese-American men. Such
differences may be due to genetic and/or environment
factors [2]. An RNA-seq study using prostate cancer tissue
from Chinese patients found two novel gene fusions which
appear to be specifically associated with Chinese patients
[3]. In this article, we will reveal an age-related Chinese
people specific feature.
2. Patients and methods
From January 2001 to February 2010, a cohort of 390 men
underwent retropubic radical prostatectomy in our insti-
tution for the treatment of clinically localized prostate
cancer. Eighty-nine cases were excluded because of
insufficient clinical data, adjuvant or neoadjuvant hor-
monal therapy, and radiotherapy. The remaining 301 cases
were included in the study and divided into two groups
based on age, with 161 (53.5%) men aged 70 years and
140 (46.5%) aged <70 years.
Two hundred and seventy-five patients were diagnosed
by ultrasound guided prostate biopsy, and 26 patients were
diagnosed by Transurethral Resection of Prostate (TURP).
Ultrasound and pelvic MRI or CT were performed before
biopsy. The indications for prostate biopsy were prostate
peripheral zone nodule detected by digital rectal exami-
nation (DRE), ultrasound, MRI or CT with any prostate spe-
cific antigen (PSA) level, or PSA Z 4e10 ng/mL and
free PSA/total PSA < 0.16 without detectable nodule, or
PSA> 10 ng/mL. In order to comparatively analyze the age
related differences, we considered Gleason score, PSA and
clinical stage (Table 1). Biochemical recurrence was
defined as two consecutive increasing PSA values of
>0.2 ng/mL.
A Chi-square test and an independent test were used to
perform a comparative analysis of clinical factors according
to age. Univariate Cox regression model and KaplaneMeier
analysis were used for examining the effect of age on the
outcomes of biochemical recurrence-free survival (BCRFS).
Mean overall follow-up for the analysis was 57 months.Table 1 Assignment of PSA, Gleason score and clinical
stage.
Process of variable assignment
PSA (ng/mL) Level 1: 0e4; Level 2: 4e10; Level 3: 10e20;
Level 4: 20
Gleason score Level 1: 3/3; Level 2: 3/4e5;
Level 3: 4e5/3e5
Clinical stage Level 1: T1a; Level 2: T1b; Level 3: T1c;
Level 4: T2a; Level 5: T2b; Level 6: T2c;
Level 7: T3aSPSS19.0 for Windows software (IBM, NY, USA) was used,
and p < 0.05 was considered statistically significant.
3. Results
Demographics and clinical characteristics are described in
Table 2. Except for PSA, there were no significant differ-
ences in other parameters between the two groups. How-
ever, the low Gleason score (3/3) rate in older group
(46.6%) was higher than that in younger group (41.4%).
Mean operation time was 200 min (range: 150e300 min).
Average blood loss was 230 (100e1100) mL. Among the 301
patients, rectum injury rate was 1.0% (3 cases), and
lymphatic leakage rate was 1.99% (6 cases). The 1 year,
2 years, 3 years and 5 years BCRFS rate were 95.0% (286
cases), 92.0% (277 cases), 91.0% (274 cases) and 89.4% (269
cases). The 5 year BCRFS rate of the old group was 92.5%
(149 in 161 cases), and it 85.7% (120 in 140 cases) in young
group.
We analyzed the relationship between the four factors
and 5 years BCRFS rate. The PSA and clinical stage were
positive risk factors, and age was a negative risk factor.
There was no relation between Gleason score and 5 years
BCRFS rate (Table 3). The survival analysis of different age
groups showed that the older patients had higher BCRFS
rate than that of the younger patients (Fig. 1).
4. Discussion
As radical prostatectomy is traditionally recommended for
patients with longer than 10 years life expectancy, many
surgeons intend to offer radical surgery to patients aged
70 years [4]. However, with the rapidly increasing elderly
population and prolonged life expectancy, more and more
old (70 years) patients with localized prostate cancer will
have longer than 10 years life expectancy [5,6]. How to
manage these patients become an important issue. It is
important to know the outcomes of radical prostatectomy
for those patients.
Several articles had focused on this question, however,
the result seemed controversial. In 2008, an US study of
4035 patients demonstrate that even though the older pa-
tients had higher clinical stage, pathology Gleason sums
and a lower frequency of organ-confined disease, there was
no difference in cancers specific survival or biochemical
progression-free probability between the younger and older
patents [7], and similar opinion appeared in another US
study [8]. With the advent of new robotic assisted RP
technique, the result seemed to be confirmed. In a RARP
study, Greco observed that except for a higher pathological
Gleason grade and longer time to return to driving, out-
comes of older patients are largely comparable to that in
younger patients [9]. However, Pfitzenmaier et al. [10]
analyzed 626 RP patients in Germany, and showed that
the 10-year PSA-free survival was 51.8% for the younger and
57.4% for the older patients respectively. Another American
and British study showed the similar result [11,12]. In Asia,
biochemical recurrence are more likely in older Korean and
Japanese patients [13,14]. Although these results are
controversial, it appeares that older patients have no bet-
ter outcome than the young patients.
Table 2 Comparison of different age groups in clinical features.
Feature Total 70 years old <70 years old p-Value
n Z 301 n Z 161 n Z 140
PSA (ng/mL)
<4, n (%) 8 (2.7) 2 (1.2) 6 (4.3) 0.2
4e10, n (%) 88 (29.2) 48 (29.8) 40 (28.6) 0.9
10e20, n (%) 108 (35.9) 64 (39.8) 44 (31.4) 0.2
20, n (%) 97 (32.2) 47 (29.2) 50 (35.7) 0.3
Mean PSA (ng/mL) 19.9 18.6 21.4 0.003
Gleason score
3/3, n (%) 133 (44.2) 75 (46.6) 58 (41.4) 0.6
3/4e5, n (%) 76 (25.2) 40 (24.8) 36 (25.7) 0.9
4e5/3e5, n (%) 92 (30.6) 46 (28.6) 46 (32.9) 0.5
Clinical stage
T1a, n (%) 22 (7.3) 10 (6.2) 12 (8.6) 0.6
T1b, n (%) 4 (1.3) 0 (0) 4 (2.9) 0.09
T1c, n (%) 91 (30.2) 49 (30.4) 42 (30.0) 1.0
T2a, n (%) 64 (21.3) 34 (21.1) 30 (21.4) 0.9
T2b, n (%) 100 (33.2) 56 (34.8) 44 (31.4) 0.6
T2c, n (%) 12 (4.0) 8 (5.0) 4 (2.9) 0.5
T3a, n (%) 8 (2.7) 4 (2.5) 4 (2.9) 0.9
Mean RPBR 0.34 0.31 0.36 0.9
PSA, prostate specific antigen; RPBR, recent positive biopsy rate.
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better outcomes than young patients. When we reviewed
the previous studies, we found that those studies were
based on the population of developed countries in which
PSA screening is universal. Compared to these patients,
Chinese patients have two unique characteristics. First,
cancer in most of the Chinese patients was not detected
by PSA screening. Because most patients with localized
prostate cancers have few symptoms, the detection of
prostate cancer is mostly depended on self medical
awareness. As a result, poor medical awareness can delay
the detection of prostate cancer in China. Because young
Chinese patients are relatively healthier and busier than
older patients who usually have more free time and more
likely to go to hospital because of other diseases. Thus the
prostate cancer diagnoses of older patients can be
confirmed timely due to better medical awareness. The
detections of prostate cancer of young patients are rela-
tively delayed because of the relatively poor medicalTable 3 The relationship between risk factors and 5 years
biochemical recurrence survival (result of Cox regression
analysis).
Regression
coefficients
Standard
error
Wald p-Value Relative
risk
PSA 0.019 0.006 9.282 0.002 1.02
Age 0.084 0.024 12.06 0.001 0.919
Gleason
score
0.259 0.174 2.202 0.138 1.295
Clinical
stage
0.316 0.143 4.872 0.027 1.371
PSA, prostate specific antigen.
Figure 1 Biochemical recurrence-free survival: the
KaplaneMeier curve for biochemical recurrence-free survival
according to the two age groups (<70 and 70 years). The log
rank test showed significant difference (p < 0.05).awareness. Second, environmental and genetic factors
may also contribute to the differences.
5. Conclusion
To conclude, the Chinese prostate cancer patients have
unique characteristics compared with patients in devel-
oped countries’. Elderly patients (70 years) have better
132 H. Wang et al.outcome than younger patients (<70 years). If the physical
condition permits, old age should not exclude patients from
radical prostatectomy.
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